Castle Biosciences Joins Newly Launched Nasdaq Texas Exchange

The company, which trades under the ticker CSTL, will begin listing on the Texas-based exchange effective today. Executives at the firm describe the decision as a strategic alignment with the state’s burgeoning life sciences sector. CEO Derek Maetzold noted that the listing honors the company’s Texas roots, while CFO Frank Stokes emphasized that the dual-exchange strategy aims to broaden investor reach without altering the firm's core operations or capital structure.

Rachel Racz, president of Nasdaq Texas, framed the partnership as a validation of the exchange’s mission to support growth-oriented, locally anchored businesses. For investors, the dual listing implies no change to existing trading mechanics or reporting obligations, as the company retains full access to Nasdaq’s global market infrastructure.